Evidence map›Paper›PMID 32803879›Full record

ReviewJournal of cellular and molecular medicine2020

The role of sphingosine 1-phosphate and its receptors in cardiovascular diseases.

Jie Ouyang, Zhihao Shu, Shuhua Chen, Hong Xiang, Hongwei Lu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jie OuyangCenter for Experimental Medical Research, the Third Xiangya Hospital of Central South University, Changsha, China.
Zhihao ShuDepartment of Cardiology, the Third Xiangya Hospital of Central South University, Changsha, China.
Shuhua ChenDepartment of Biochemistry, School of Life Sciences of Central South University, Changsha, China.
Hong XiangCenter for Experimental Medical Research, the Third Xiangya Hospital of Central South University, Changsha, China.
Hongwei LuCenter for Experimental Medical Research, the Third Xiangya Hospital of Central South University, Changsha, China.ORCID 0000-0001-8005-142X
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are many different types of cardiovascular diseases, which impose a huge economic burden due to their extremely high mortality rates, so it is necessary to explore the underlying mechanisms to achieve better supportive and curative care outcomes. Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator with paracrine and autocrine activities that acts through its cell surface S1P receptors (S1PRs) and intracellular signals. In the circulatory system, S1P is indispensable for both normal and disease conditions; however, there are very different views on its diverse roles, and its specific relevance to cardiovascular pathogenesis remains elusive. Here, we review the synthesis, release and functions of S1P, specifically detail the roles of S1P and S1PRs in some common cardiovascular diseases, and then address several controversial points, finally, we focus on the development of S1P-based therapeutic approaches in cardiovascular diseases, such as the selective S1PR1 modulator amiselimod (MT-1303) and the non-selective S1PR1 and S1PR3 agonist fingolimod, which may provide valuable insights into potential therapeutic strategies for cardiovascular diseases.

Indexed as

AnimalsCardiovascular DiseasesHumansLysophospholipidsModels, BiologicalSignal TransductionSphingosineSphingosine-1-Phosphate ReceptorsLysophospholipidsSphingosinesphingosine 1-phosphateSphingosine-1-Phosphate Receptorscardiovascular diseasesphingosine 1-phosphatesphingosine 1-phosphate receptor

Identifiers

PMID32803879
PMCPMC7521328
OpenAlexW3081371029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.